普萘洛尔用于婴儿血管瘤及恶性肿瘤治疗的精准药学研究

Precision Pharmacy Study of Propranolol for the Treatment of Infantile Hemangioma and Malignant Tumors

普萘洛尔作为一种非选择性、亲脂性的β-肾上腺素能受体阻断药,主要用于治疗高血压、心律失常和焦虑等,并已成为婴儿血管瘤的一线用药。大量的临床数据表明,普萘洛尔用于治疗婴儿血管瘤在疗效和不良反应上显示出一定的个体差异。造成差异的原因可能与药物靶点、药物代谢酶的遗传变异有关。此外,越来越多的临床前和临床研究表明,普萘洛尔也可用于治疗不同类型的恶性肿瘤。该文重点总结了普萘洛尔用于肿瘤治疗的精准药学研究,并讨论了其目前在肿瘤治疗中的应用瓶颈,以有助于普萘洛尔的临床再利用。

Propranolol,as a non-selective,lipophilic beta-adrenergic receptor blocker,is mainly used for treating hypertension,arrhythmia,and anxiety,and has become the first-line drug for infantile hemangioma in clinical practice.A large amount of clinical data has shown that propranolol for the treatment of infancy hemangioma shows some individual differences in efficacy and adverse effects.The differences may be related to receptor variation,drug metabolism,and other reasons.In addition,a growing number of preclinical and clinical studies suggest that propranolol can also be used to treat other different types of tumors.In this review,we focus on summarizing studies on the precision pharmacy of propranolol for antitumor therapy and discuss the bottlenecks in its current use for cancer treatment,which help to shed light on the repurposing of propranolol.